A National Registry on Chinese Patients With Cystic Fibrosis

A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Cystic Fibrosis (CF-CHINA)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05289245

Enrollment

200

Registered

2022-03-21

Start date

2022-04-01

Completion date

2032-10-01

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Function

Brief summary

Cystic fibrosis (CF) is a rare autosomal recessive disease involving multiple organs, especially the lungs and digestive organs. It is most commonly seen in Caucasians. Only a few Chinese CF patients have been described in literature, taking into account the large population of China. The main objectives of this study are to accurately evaluate the prevalence of CF, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Fulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with no respiratory infections for nearly 4 weeks; Subjects (or their guardians) signed informed consent.

Exclusion criteria

Patients with other bronchiectasis who did not meet the inclusion criteria; Those with severe cardiac or renal disease

Design outcomes

Primary

Measure	Time frame	Description
Change in spirometry (FEV1 and FVC) of lymphangioleiomyomatosis patients.	10 years	Spirometry will be evaluated at baseline and through study completion, an average of 3 years.

Countries

China

Contacts

Primary ContactXinlun Tian, M.D.

tianxl@pumch.cn86-10-69155039

Outcome results